Member Info for Bobat123

More buys then sells so far today and mms holding this back. Total manipulation going on

# Trades 56

Vol. Sold 1,560,727

Sold Value £7.14k

Vol. Bought 6,292,950

Bought Value £29.46k

Got no money. Placing done in may £210k. No money left. Another placing due. dyor

I am pleased to present the interim results for the six-month period from 1 January 2025 to 30 June 2025. The period was a transformative one for the Company and reflects my first 6 months as CEO where consolidation and redirection in terms of funding and operational focus has been key. From a funding perspective, shortly after the period end major (c.20%) shareholders Gathoni Muchai Investments ("GMI") committed a further £1.5m investment thorough an unsecured loan facility, bringing their total investment commitment to £2m. Application of funds, once fully drawn, will be applied towards working capital, the settlement of the remaining purchase consideration to conclude the acquisition of the Kabwe Project from Leopard Exploration and Mining ("LEM"), the restart of the Rukwa mine and initial exploration at Kabwe. The initial tranche of £500,000 has, post period, been fully drawn.

Drawdown notices under Tranche 2 have commenced post period and, as updated to the market on 18 September 2025, GMI are in process of completing alternate means to expedite payment to the Company. GMI have advised that the intended transfer by alternate means will now be delayed beyond month end as originally indicated, but that they expect to conclude the transfer by 15th October 2025.

Shares not in public hands

A total of 36.9% of the Company's securities are not in public hands.

Agreed. Everytime this heads to 0.6 plus mms drops this back to 0.5.

Company is aware of the completion of the NHSE CYP2C19 pilot assessing logistics of deploying as a service at scale via laboratory or point of care, and what, based on interim assessment it anticipates to be a positive outcome supporting the role and impact of rapid CYP2C19 genetic testing in stroke patients, it has not yet been made aware of a publication date by NHSE and cannot confirm the dates reportedly conveyed in the communication.

Details of the interim assessment can be found:

https://www.nw-gmsa.nhs.uk/about-us/our-projects/genomic-networks-excellence/pharmacogenomics-and-medicines-optimisation-genomic-network-excellence/clopidogrel-pilot-project-cyp2c19-genetic-testing-stroke-and-tia-patients

2-1 more buys then sells so far.

# Trades 104

Vol. Sold 6,027,753

Sold Value £31.09k

Vol. Bought 10,889,166

Bought Value £61.17k

More buys getting printed.

Rns Out. Buys coming in???

https://www.lse.co.uk/rns/AST/update-on-energy-charter-treaty-claim-hrtixlt2n7howra.html

Placing done. This should be over 15p plus. Ignore the deramping crew.

Director also bought in earlier Rns

Dr. Eric Leire, CEO of the Company, purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.

Director also bought in earlier rns

Dr. Eric Leire, CEO of the Company, purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.

Funded as well..

enflow Confirms Approximately €4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to reaffirm the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, supporting the development of its lead gene therapy candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). Read the RNS announcing this grant here.

The support package spans a three-year development program, aligned with Genflow's existing clinical roadmap. All project-related expenses incurred in 2025 will be considered eligible. While initial disbursement is pending the completion of standard administrative procedures on the government's side, Genflow has taken proactive steps to ensure the continuity of its GF-1002 program and confirms that progress remains on track with no delays to planned research or development activities.

Dr. Eric Leire, CEO of Genflow, commented: "We greatly appreciate the continued support from the Wallonia Region. The €4 million in non-dilutive funding represents a significant endorsement of our science and our strategy. We remain fully focused on advancing GF-1002 through the next stage of development and have ensured that operations proceed uninterrupted as the program moves forward."

Mikey279 Premium Member. Please leave peeps to them own. It is their money and they can do what they want. Why do you want to be Donald Trump and save them. Each to their own.

I am still in here took some profits and moved into OMI. Both look good. Am holding for over 20p plus here. 10 is gone. gla

Sold half and moved into OMI.

MMs flapping for shares. They are waiting for sellers and nobody selling.

Bought in. MMs have no stock. Can see this moving up daily till next rns.

Hopefully some news and good week ahead

Hopefully some news and good week ahead

As at 31 December 2024, the Group held cash balances of £0.91 million. Since March 2023, however, the Group has been unable to meet its scheduled repayments of principal and interest on its term loans.